These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21851800)

  • 1. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies.
    Tubach F; Lamarque-Garnier V; Castot A;
    Therapie; 2011; 66(4):355-62, 347-54. PubMed ID: 21851800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs and indications in 2010: inadequate assessment; patients at risk.
    Prescrire Int; 2011 Apr; 20(115):105-7, 109-10. PubMed ID: 21648217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A call for international harmonization in therapeutic risk management.
    Hirst C; Cook S; Dai W; Perez-Gutthann S; Andrews E
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):839-49; discussion 850-1. PubMed ID: 16981215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International guidelines on post-authorisation research and surveillance. European Economic Community.
    Herbold M
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):62-4. PubMed ID: 9035230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of scientific evidence of risks and benefits in determining risk management policies for medications.
    Andrews E; Dombeck M
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
    Lodén M; Ungerth L; Serup J
    Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of postmarketing research.
    Venulet J
    Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment and management of occupational exposure to pesticides in agriculture.
    Maroni M; Fanetti AC; Metruccio F
    Med Lav; 2006; 97(2):430-7. PubMed ID: 17017381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk management and post-marketing surveillance of CNS drugs.
    Henningfield JE; Schuster CR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory decisions and consumers.
    Rawlins MD
    Med Toxicol; 1986; 1 Suppl 1():128-9. PubMed ID: 3821428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Food and Drug Administration risk evaluation and mitigation strategy.
    Craig DS
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European perspective on risk management and drug safety.
    Raine J; Wise L; Blackburn S; Eichler HG; Breckenridge A
    Clin Pharmacol Ther; 2011 May; 89(5):650-4. PubMed ID: 21512526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Communicating the risks and benefits of medicines.
    Schmid EF; Smith DA; Ryder SW
    Drug Discov Today; 2007 May; 12(9-10):355-64. PubMed ID: 17467571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to improve the clinical development paradigm and its division into phases I, II and III.
    Bamberger M; Moore N; Lechat P;
    Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.